Get started
Author

Shivan Sivakumar

In situ multi-modal characterization of pancreatic cancer reveals tumor cell identity as a defining factor of the surrounding microenvironment
2026 · Anna Lyubetskaya, Brian Rabe, et al. · Cell Reports · 8
Spatial Proteomics Uncovers Immune Cell Neighborhoods and Tumor-Immune Interfaces in Pancreatic Ductal Adenocarcinoma
2026 · Jason Yeung, Yunhao Bai, et al. · Molecular & Cellular Proteomics
PDF
Linking Targeted Pancreatic Cancer Genes With Metabolic Disorders: A Cross‐Species Translational Pathway
2026 · Dipanwita Nath, Caitlin Ditchfield, et al. · Cancer Medicine
An early safety study testing a drug combination given before possible surgery for people with pancreatic cancer that can’t be easily removed yet or hasn’t spread far
2026 · Shivan Sivakumar, Phillip Trieu · http://isrctn.com/
Hallmarks of adaptive immunity in a metastatic clear cell renal cell carcinoma (ccRCC) long-term elite survivor
2025 · Felicia Tucci, Edward Drydale, et al. · bioRxiv (Cold Spring Harbor Laboratory)
307 Baseline Gut Microbiome Composition is Associated with Response to Neoadjuvant Chemotherapy in Pancreatic Cancer Patients
2025 · James Halle-Smith, Katie Fung, et al. · British journal of surgery
PDF
Cardiovascular Risk Factor Reporting in Immune Checkpoint Inhibitor Trials for Lung Cancer: A Systematic Review
2024 · R. Ma, S. Sivakumar, et al. · Heart Lung and Circulation
PDF
P-5 Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 +/- spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)
2022 · S. Sivakumar, T. Macarulla, et al. · Annals of Oncology
Works count: 9
Citation count: 8
H-index: 1
I10-index:
Year
Topic
Type